SLACS technology marks a revolutionary leap in DNA analysis, offering unparalleled insights and benefits that surpass the capabilities of conventional approaches. This cutting-edge technology facilitates the integration of cellular spatial arrangements with high-accuracy molecular analysis, proving to be especially advantageous in exploring the complex spatial organisation of genetic information.

The core achievements of SLACS technology in DNA research

  • Revolutionising DNA Research: SLACS technology is redefining the landscape of DNA analysis by seamlessly merging intricate anatomical mapping with the complexities of genomics. This pioneering approach propels research into previously unexplored territories, opening new avenues for scientific discovery and precision medicine.

  • In-Depth Subclone Identification: A groundbreaking discovery facilitated by SLACS is the identification of three distinct genetic subclones within specific breast cancer tissues. Each subclone has its unique genetic variations, which allows for a deeper, more nuanced genomic understanding of the cancer, advancing the frontiers of precision medicine.

  • Advanced Visualisation Techniques: SLACS enables researchers to visualise and map the distribution and evolution of genetic subclones. This capability provides an unprecedented view into their development and potential impact on disease progression, thereby enriching the field with detailed insights.

  • Constructing Genomic Landscapes: The construction of a comprehensive three-dimensional cancer genomic map by SLACS highlights genetic subclones associated with benign cancer phenotypes. This innovation significantly enriches our understanding of the spatial genomics of cancer.

  • Cutting-edge Analytical Approaches

  • CNA and SNV Analyses: SLACS utilises Whole Exome Sequencing (WES) to conduct in-depth examinations of Copy Number Alterations (CNAs) and Single Nucleotide Variants (SNVs). This analysis reveals the evolutionary history of cancer cells and correlates genetic mutations with histopathological features.

  • Unveiling Genetic Heterogeneity: The technology is instrumental in uncovering the genetic heterogeneity within cancer cells, providing a more detailed understanding of tumour composition and enhancing the overall grasp of cancer biology.

  • Integration with Bulk RNA Sequencing for MRD Detection

    The integration of SLACS-DNA-seq with bulk RNA sequencing significantly improves the accuracy of minimal residual disease detection across various cancer subclones. This has a profound impact on managing disease progression and treatment responses.

    Advancing Haematopoiesis Understanding

    Applying SLACS-DNA-seq to haematopoiesis studies has revealed the genetic and regulatory mechanisms behind blood cell development and disorders, marking a pivotal advance in haematological research.

    *Jeong, Dajeong, et al. "Hema-seq reveals genomic aberrations in a rare simultaneous occurrence of hematological malignancies." Cell Reports Methods 3.10 (2023).

    Applications in Haematological Sample Analysis

    The application of SLACS-DNA-seq to haematological samples represents a significant leap forward in diagnosing and studying blood diseases. It enables the accurate identification of genetic mutations and diversities in blood and bone marrow cells, leading to improved biomarker detection, risk stratification, and targeted therapy selection, thereby enhancing treatment efficacy and patient prognoses.

    *Jeong, Dajeong, et al. "Hema-seq reveals genomic aberrations in a rare simultaneous occurrence of hematological malignancies." Cell Reports Methods 3.10 (2023).